Tinlarebant is an oral therapy designed to reduce the accumulation of vitamin A based toxins that cause retinal disease.

The event will focus on UNITY’s ongoing Phase 2b ASPIRE study, which is evaluating foselutoclax (UBX1325) head-to-head against aflibercept in DME. UNITY Biotechnology, Inc. is set to host an in-person ...

Applied Science, Inc. (ASI) is expanding its AdaptivMD chronic care workflow technology to Sierra Family Health Center (SFHC) and Western Sierra Medical Clinic (WSMC). ASI has integrated a retinal ...

The European Association for Vision and Eye Research 27th EVER Congress will be held in Valencia, Spain, November 3 – 5, 2024. Thierry Bordet, CSO of PulseSight Therapeutics, said spoke about this ...

Remidio, received CDSCO approval for its Medios DR AI, which is used with its portable retinal cameras. This approval comes after the same solution received CE marking under EU-MDR guidelines and HSA ...

According to the company, the axitinib injectable suspension achieved all primary and secondary outcomes and maintained stable visual acuity and anatomical control over 9 months. There were no ocular ...

Everads suprachoroidal delivery technology is designed to enable safe and effective in-office delivery of therapies to the choroidal and retinal tissues via the suprachoroidal space. Everads Therapy ...

In a study, a team of UCLA investigators detail a deep-learning model pre-trained on 2D scans that accurately predicts disease-risk factors from 3D medical-scan modalities. A team of researchers at ...

In a study, a team of UCLA investigators detail a deep-learning model pre-trained on 2D scans that accurately predicts disease-risk factors from 3D medical-scan modalities. Toku’s AI technology, CLAiR ...

This patented technology is designed to enhance the light sensitivity of a multi-characteristic opsin developed by Nanoscope as a gene therapy.

Efferocytosis’ role in retinopathy is largely unknown despite knowledge of the process in other diseases.